Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13550989 | 0.81 | CYP1A2 (0.37) | CYP1A2GRM2DAGLAPRKCA | |
| SCHEMBL7887401 | 0.77 | PTGS1 (0.42) | CYP1A2PRKCDPTGS1PTGS2MGLL | |
| SCHEMBL28476739 | 0.69 | TP53 (0.44) | CYP1A2TP53DAGLAPRKCA | |
| SCHEMBL14581339 | 0.69 | PRKCA (0.47) | CYP1A2PRKCDDAGLAPRKCA | |
| SCHEMBL29056457 | 0.69 | TP53 (0.44) | CYP1A2TP53DAGLAPRKCA | |
| SCHEMBL23563177 | 0.69 | PRKCA (0.47) | CYP1A2PRKCDDAGLAPRKCA | |
| SCHEMBL10998132 | 0.69 | TP53 (0.44) | CYP1A2TP53DAGLAPRKCA | |
| SCHEMBL31134790 | 0.69 | TP53 (0.44) | CYP1A2TP53DAGLAPRKCA | |
| SCHEMBL5492794 | 0.69 | TP53 (0.44) | CYP1A2TP53DAGLAPRKCA | |
| SCHEMBL3477470 | 0.69 | TP53 (0.44) | CYP1A2TP53DAGLAPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449343-B2 | Device for dispensing and applying a liquid | ACRUX DDS PTY LTD (AU) | 2019-10-22 | — | — | US | claimed |
| EP-3542785-A1 | CONTROLLED RELEASE OF ACTIVES IN SKIN | Rutgers, The State University of New Jersey (US) | 2019-09-25 | — | — | EP | claimed |
| EP-2114377-B1 | CONTROLLED RELEASE OF ACTIVES IN SKIN | UNIV RUTGERS (US) | 2018-10-17 | — | — | EP | claimed |
| US-20170157378-A1 | DEVICE FOR DISPENSING AND APPLYING A LIQUID | ACRUX DDS PTY LTD (AU) | 2017-06-08 | — | — | US | claimed |
| EP-3074081-A1 | A DEVICE FOR DISPENSING AND APPLYING A LIQUID | Acrux DDS Pty Ltd (AU) | 2016-10-05 | — | — | EP | claimed |
| WO-2015081078-A1 | A DEVICE FOR DISPENSING AND APPLYING A LIQUID | ACRUX DDS PTY LTD. (AU) | 2015-06-04 | — | — | WO | claimed |
| US-8414871-B2 | Controlled releases of actives in skin | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-04-09 | — | — | US | claimed |
| EP-2266533-A2 | Transdermal delivery rate control using amorphous pharmaceutical compositions | Acrux DDS Pty Ltd (AU) | 2010-12-29 | — | — | EP | claimed |
| US-20100166674-A1 | TRANSDERMAL DELIVERY RATE CONTROL USING AMORPHOUS PHARMACEUTICAL COMPOSITIONS | ACRUX DDS PTY LTD | 2010-07-01 | — | — | US | claimed |
| US-20090317472-A1 | CONTROLLED RELEASES OF ACTIVES IN SKIN | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-12-24 | — | — | US | claimed |
| US-20080027033-A1 | Method and Composition for Treatment of Cutaneous Lesions | ACRUX DDS PTY LTD | 2008-01-31 | — | — | US | claimed |
| US-20070275943-A1 | Method and Composition for Treatment or Prophylaxis of Amyloidosis Disorders | ACRUX DDS PTY LTD. | 2007-11-29 | — | — | US | claimed |
| EP-1684761-A1 | METHOD AND COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF AMYLOIDOSIS DISORDERS | Acrux DDS Pty Ltd (AU) | 2006-08-02 | — | — | EP | claimed |
| EP-1684760-A1 | METHOD AND COMPOSITION FOR TREATMENT OF CUTANEOUS LESIONS | Acrux DDS Pty Ltd (AU) | 2006-08-02 | — | — | EP | claimed |
| US-20050175680-A1 | drug and a dermal penetration enhancer that form an amorphous deposit upon evaporation of the volatile carrier to control the extent and/or profile of transdermal release of a drug | ACRUX DDS PTY LTD. | 2005-08-11 | — | — | US | claimed |
| WO-2005049026-A1 | METHOD AND COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF AMYLOIDOSIS DISORDERS | ACRUX DDS PTY LTD (AU) | 2005-06-02 | — | — | WO | claimed |
| WO-2005049025-A1 | METHOD AND COMPOSITION FOR TREATMENT OF CUTANEOUS LESIONS | ACRUX DDS PTY LTD (AU) | 2005-06-02 | — | — | WO | claimed |
| EP-1534235-A1 | TRANSDERMAL DELIVERY RATE CONTROL USING AMORPHOUS PHARMACEUTICAL COMPOSITIONS | Acrux DDS Pty Ltd (AU) | 2005-06-01 | — | — | EP | claimed |
| US-20050002868-A1 | Method of treatment of a female suffering from androgen insufficiency | ACRUX DDS PTY LTD. | 2005-01-06 | — | — | US | claimed |
| WO-2004000263-A1 | TRANSDERMAL DELIVERY RATE CONTROL USING AMORPHOUS PHARMACEUTICAL COMPOSITIONS | ACRUX DDS PTY LTD (AU) | 2003-12-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317472-A1 | CONTROLLED RELEASES OF ACTIVES IN SKIN | CUTA, ABCB4, ABCF1 | CYP1A2 93/4885GRM2 4813/4885TYR 328/4885 |
| US-10449343-B2 | Device for dispensing and applying a liquid | PRLHR, EXOSC9, GNRHR | CYP1A2 3086/4885GRM2 3107/4885TYR 4690/4885 |
| US-20170157378-A1 | DEVICE FOR DISPENSING AND APPLYING A LIQUID | PRLHR, EXOSC9, GNRHR | CYP1A2 3086/4885GRM2 3107/4885TYR 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.